%0 Journal Article
%A Wolffenbuttel, B. H. R.
%A Van Gaal, L.
%A Duran-Garcia, S.
%A Han, J.
%T Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes
%D 2016
%@ 1462-8902
%U http://hdl.handle.net/10668/18985
%X This post hoc analysis assessed the evidence behind common reimbursement practices by evaluating the relationship of body mass index (BMI) ranges (35 kg/m(2)) with treatment effects of exenatide twice daily among patients with type 2 diabetes. Patients received exenatide twice daily added to insulin glargine in two 30-week studies (exenatide twice daily vs insulin lispro, n = 627; exenatide twice daily vs placebo, n = 259). No association of baseline BMI with changes in efficacy variables was observed. Glycated haemoglobin (HbA1c) reductions were significant (p
%K body mass index
%K exenatide twice daily
%K type 2 diabetes
%K Peptide-1 receptor agonist
%K Basal insulin
%K Bolus insulin
%K Safety
%K Liraglutide
%K Management
%K Degludec
%~